{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:26:22Z","timestamp":1793643982831,"version":"4.5.1"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cca.2026.120843","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:03:35Z","timestamp":1768320215000},"page":"120843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tissue polypeptide antigen as a non-invasive bladder Cancer biomarker"],"prefix":"10.1016","volume":"583","author":[{"given":"Neeraj Kumar","family":"Fuloria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmashini","family":"Gnanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish Vasanth","family":"Dhandapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangita","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkanya","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.120843_bb0005","article-title":"Bladder cancer biomarkers: current approaches and future directions","volume":"14\u20132024","author":"Ahangar","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.120843_bb0010","doi-asserted-by":"crossref","first-page":"1114203","DOI":"10.3389\/fonc.2023.1114203","article-title":"Identifying novel biomarkers associated with bladder cancer treatment outcomes","volume":"13","author":"Castaneda","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.cca.2026.120843_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071650","article-title":"Noninvasive urine-based tests to diagnose or detect recurrence of bladder Cancer","volume":"13","author":"Charpentier","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.cca.2026.120843_bb0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.urolonc.2024.12.263","article-title":"Development of point-of-care tests for urinary bladder cancer \u2013 an historic review and view to future prospectives","volume":"43","author":"Ecke","year":"2025","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0030","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.21037\/tau-20-1327","article-title":"Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?","volume":"10","author":"Humayun-Zakaria","year":"2021","journal-title":"Translational Andrology and Urology"},{"key":"10.1016\/j.cca.2026.120843_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117225","article-title":"A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1)","volume":"178","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"4a","key":"10.1016\/j.cca.2026.120843_bb0040","first-page":"2609","article-title":"Serum tissue polypeptide antigen (TPA): monoclonal or polyclonal radio-immunometric assay for the follow-up of bladder cancer","volume":"19","author":"Bennink","year":"1999","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.cca.2026.120843_bb0045","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.1997.15.12.3446","article-title":"Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study","volume":"15","author":"Maulard-Durdux","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2026.120843_bb0050","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1074\/mcp.M115.051524","article-title":"Comparative tissue proteomics of microdissected specimens reveals novel candidate biomarkers of bladder Cancer *","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cell. Proteomics"},{"issue":"56","key":"10.1016\/j.cca.2026.120843_bb0055","doi-asserted-by":"crossref","first-page":"30731","DOI":"10.18632\/oncotarget.24578","article-title":"Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens","volume":"9","author":"Tsai","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000226782","article-title":"Tissue polypeptide antigen (TPA) in urinary bladder Cancer cytology: a follow-up study","volume":"47","author":"Senatore","year":"2009","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.cca.2026.120843_bb0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/BLC-160054","article-title":"A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder Cancer","volume":"2","author":"D\u2019Costa","year":"2016","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2353\/ajpath.2006.050601","article-title":"Profiling bladder cancer using targeted antibody arrays","volume":"168","author":"Sanchez-Carbayo","year":"2006","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1074\/mcp.M900294-MCP200","article-title":"Bladder Cancer-associated protein, a potential prognostic biomarker in human bladder Cancer *<sup> <\/sup>","volume":"9","author":"Moreira","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0080","first-page":"1","article-title":"Biomarkers for bladder cancer management: present and future","volume":"2","author":"Ye","year":"2014","journal-title":"Am. J. Clin. Experimental Urol."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1021\/acsptsci.4c00663","article-title":"A comprehensive review of current approaches in bladder Cancer treatment","volume":"8","author":"Kumbham","year":"2025","journal-title":"ACS Pharmacology & translational Science"},{"key":"10.1016\/j.cca.2026.120843_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672262","article-title":"Treating bladder Cancer: engineering of current and next generation antibody-Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics","volume":"11","author":"Bogen","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0005-2795(80)90228-7","article-title":"Biochemical properties of tissue polypeptide antigen","volume":"624","author":"L\u00fcning","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.cca.2026.120843_bb0100","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1002\/j.1460-2075.1984.tb02198.x","article-title":"Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker","volume":"3","author":"Weber","year":"1984","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00262097","article-title":"Tissue polypeptide antigen (TPA), some cytokeratins and epithelial membrane antigen (EMA) in normal, inflamed and malignant urothelium","volume":"15","author":"Carbin","year":"1987","journal-title":"Urol. Res."},{"issue":"7","key":"10.1016\/j.cca.2026.120843_bb0110","first-page":"1007","article-title":"On the nature of serological tissue polypeptide antigen (TPA); monoclonal keratin 8, 18, and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum","volume":"5","author":"Mellerick","year":"1990","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1432-1033.1996.00309.x","article-title":"Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18","volume":"241","author":"Rydlander","year":"1996","journal-title":"Eur. J. Biochem."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0009-8981(97)00129-0","article-title":"Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer","volume":"266","author":"Kashiwabara","year":"1997","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"issue":"3","key":"10.1016\/j.cca.2026.120843_bb0125","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1378\/chest.93.3.565","article-title":"Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer","volume":"93","author":"Buccheri","year":"1988","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.cca.2026.120843_bb0130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00262980","article-title":"Urine-TPA (tissue polypeptide antigen), flow cytometry and cytology as markers for tumor invasiveness in urinary bladder carcinoma","volume":"17","author":"Carbin","year":"1989","journal-title":"Urol. Res."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0135","first-page":"69","article-title":"[blood and urine determinations of tissue polypeptide antigen in patients with bladder carcinoma], Minerva urologica e nefrologica =","volume":"42","author":"Tizzani","year":"1990","journal-title":"The Italian J. Urol. Nephrol."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0140","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/1097-0142(19940115)73:2<394::AID-CNCR2820730226>3.0.CO;2-Y","article-title":"Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study","volume":"73","author":"Maulard","year":"1994","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1023\/A:1007103009313","article-title":"Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma","volume":"31","author":"Stefanovi\u0107","year":"1999","journal-title":"Int. Urol. Nephrol."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0150","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00005392-200102000-00081","article-title":"Urine based markers of urological malignancy","volume":"165","author":"Konety","year":"2001","journal-title":"J. Urol."},{"issue":"11","key":"10.1016\/j.cca.2026.120843_bb0155","article-title":"Stress Intensity Factors for Embedded, Surface, and Corner Cracks in Finite-Thickness Plates Subjected to Tensile Loading","volume":"vol. 14","author":"Toribio","year":"2021","journal-title":"Materials (Basel, Switzerland)"},{"issue":"8","key":"10.1016\/j.cca.2026.120843_bb0160","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s42256-024-00868-w","article-title":"A transformer-based weakly supervised computational pathology method for clinical-grade diagnosis and molecular marker discovery of gliomas","volume":"6","author":"Jiang","year":"2024","journal-title":"Nature Machine Intelligence"},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/172460088900400103","article-title":"Tissue and serum TPA in subjects at risk for bladder cancer","volume":"4","author":"Giovagnoli","year":"1989","journal-title":"Int. J. Biol. Markers"},{"issue":"5","key":"10.1016\/j.cca.2026.120843_bb0170","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00262980","article-title":"Urine-TPA (tissue polypeptide antigen), flowcytometry and cytology as markers for tumor invasiveness in urinary bladder carcinoma","volume":"17","author":"Carbin","year":"1989","journal-title":"Urol. Res."},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0175","first-page":"37","article-title":"Tissue polypeptide antigen (TPA) in urinary bladder cancer cytology: a follow-up study","volume":"47","author":"Senatore","year":"1990","journal-title":"Oncology"},{"key":"10.1016\/j.cca.2026.120843_bb0180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1574893616666210708143556","article-title":"Cervical Cancer metastasis and recurrence risk prediction based on deep convolutional neural network","volume":"17","author":"Ye","year":"2022","journal-title":"Curr. Bioinforma."},{"issue":"3","key":"10.1016\/j.cca.2026.120843_bb0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ki.1979.136","article-title":"Tissue antigens in normal and pathologic urine samples: a review","volume":"16","author":"Rosenmann","year":"1979","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0190","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/172460089400900207","article-title":"Cytokeratins and tissue polypeptide antigen","volume":"9","author":"Sundstr\u00f6m","year":"1994","journal-title":"Int. J. Biol. Markers"},{"issue":"4b","key":"10.1016\/j.cca.2026.120843_bb0195","first-page":"2345","article-title":"Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease","volume":"16","author":"van Dalen","year":"1996","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.cca.2026.120843_bb0200","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.1997.15.12.3446","article-title":"Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study","volume":"15","author":"Maulard-Durdux","year":"1997","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.120843_bb0205","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0169-5002(01)00347-6","article-title":"Lung tumor markers of cytokeratin origin: an overview","volume":"34","author":"Buccheri","year":"2001","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.cca.2026.120843_bb0210","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/sj.cdd.4400988","article-title":"Apoptosis and keratin intermediate filaments","volume":"9","author":"Oshima","year":"2002","journal-title":"Cell Death Differ."},{"issue":"4c","key":"10.1016\/j.cca.2026.120843_bb0215","first-page":"2861","article-title":"Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases","volume":"27","author":"Liska","year":"2007","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.cca.2026.120843_bb0220","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.oraloncology.2007.10.008","article-title":"Cytokeratin fragments in the serum: their utility for the management of oral cancer","volume":"44","author":"Sawant","year":"2008","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0225","first-page":"1","article-title":"Tumor markers in clinical practice: general principles and guidelines","volume":"30","author":"Sharma","year":"2009","journal-title":"Indian journal of medical and paediatric oncology\u202f: official journal of Indian Society of Medical & paediatric Oncology"},{"issue":"5","key":"10.1016\/j.cca.2026.120843_bb0230","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ndt\/gfg080","article-title":"Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity","volume":"18","author":"Stam","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0235","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/0886022X.2016.1148523","article-title":"Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers","volume":"38","author":"Amiri","year":"2016","journal-title":"Ren. Fail."},{"key":"10.1016\/j.cca.2026.120843_bb0240","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/685641","article-title":"Usefulness of traditional serum biomarkers for management of breast cancer patients","volume":"2013","author":"Mirabelli","year":"2013","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.cca.2026.120843_bb0245","doi-asserted-by":"crossref","DOI":"10.1177\/1010428318776169","article-title":"Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA","volume":"40","author":"Duffy","year":"2018","journal-title":"Tumour Biol."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0250","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/biom13040675","article-title":"Plasma Cytokeratin-18 fragment level reflects the metabolic phenotype in obesity","volume":"13","author":"Goralska","year":"2023","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0255","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1109\/TCBB.2020.2973148","article-title":"FUNMarker: fusion network-based method to identify prognostic and heterogeneous breast Cancer biomarkers","volume":"18","author":"Li","year":"2021","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0260","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0090-4295(03)00263-2","article-title":"Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer","volume":"62","author":"Men\u00e9ndez L\u00f3pez","year":"2003","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0265","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/imm.13793","article-title":"Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy","volume":"173","author":"Wang","year":"2024","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0270","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000217913","article-title":"Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma","volume":"15","author":"Shabana","year":"1994","journal-title":"Tumour biology\u202f: the journal of the International Society for Oncodevelopmental Biology and Medicine"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0275","first-page":"97","article-title":"Splanchnic portal circulation (enhancement of radiologic image intensity and of visibility of collateral branches with prostaglandin E1)","volume":"34","author":"Widman","year":"1997","journal-title":"Arq. Gastroenterol."},{"issue":"5","key":"10.1016\/j.cca.2026.120843_bb0280","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/1522-7243(200009\/10)15:5<283::AID-BIO593>3.0.CO;2-F","article-title":"Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer","volume":"15","author":"Findeisen","year":"2000","journal-title":"Luminescence"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/33.2.3968422","article-title":"Distribution of tissue polypeptide antigen (TPA) in normal human tissues: immunohistochemical study on unfixed, methanol-, ethanol-, and formalin-fixed tissues","volume":"33","author":"Nathrath","year":"1985","journal-title":"J. Histochem. Cytochem."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0290","first-page":"118","article-title":"Tissue polypeptide antigen in normal and neoplastic urinary bladder. Preliminary reports","volume":"44","author":"Senatore","year":"1987","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.cca.2026.120843_bb0295","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jvh.13886","article-title":"CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes","volume":"30","author":"Ning","year":"2023","journal-title":"J. Viral Hepat."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0300","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/172460089400900405","article-title":"Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen","volume":"9","author":"Correale","year":"1994","journal-title":"Int. J. Biol. Markers"},{"issue":"3","key":"10.1016\/j.cca.2026.120843_bb0305","first-page":"213","article-title":"Tissue polypeptide antigen in the follow-up of patients with urinary bladder cancer compared with conventional urine cytology","volume":"13","author":"Bantis","year":"2010","journal-title":"Hell. J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.cca.2026.120843_bb0310","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.urology.2007.06.229","article-title":"MP-04.03: the value of tissue polypeptide antigen (TPA) in the after care patients with bladder cancer: relationship with conventional urine cytology","volume":"70","author":"Bantis","year":"2007","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0315","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/S0022-5347(05)68076-7","article-title":"Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer","volume":"162","author":"S\u00e1nchez-Carbayo","year":"1999","journal-title":"J. Urol."},{"issue":"4b","key":"10.1016\/j.cca.2026.120843_bb0320","first-page":"2205","article-title":"Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer","volume":"16","author":"van Poppel","year":"1996","journal-title":"Anticancer Res."},{"issue":"4b","key":"10.1016\/j.cca.2026.120843_bb0325","first-page":"2173","article-title":"TPA prognostic value in superficial bladder cancer","volume":"16","author":"Filella","year":"1996","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0330","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00257178","article-title":"Significance of plasma tissue polypeptide antigen determination for diagnosis and follow-up of urothelial bladder cancer","volume":"12","author":"Adolphs","year":"1984","journal-title":"Urol. Res."},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0335","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1464-410X.1981.tb03264.x","article-title":"The clinical significance of tissue polypeptide antigen (TPA) in the urine of bladder cancer patients","volume":"53","author":"Kumar","year":"1981","journal-title":"Br. J. Urol."},{"issue":"8","key":"10.1016\/j.cca.2026.120843_bb0340","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/BF01211809","article-title":"Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract","volume":"118","author":"van der Gaast","year":"1992","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.120843_bb0345","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cca.2013.08.021","article-title":"Harmonization of laboratory testing \u2014 current achievements and future strategies","volume":"432","author":"Tate","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.120843_bb0350","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cca.2017.05.035","article-title":"Stability of lyophilized pooled sera as quality control materials for tumor marker assays in external quality assessment","volume":"471","author":"Ahn","year":"2017","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0355","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1515\/cclm-2024-0696","article-title":"External quality assessment-based tumor marker harmonization simulation; insights in achievable harmonization for CA 15-3 and CEA","volume":"63","author":"Rossum","year":"2025","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0360","first-page":"15","article-title":"Harmonization of clinical laboratory information - current and future strategies","volume":"27","author":"Plebani","year":"2016","journal-title":"Ejifcc"},{"issue":"5","key":"10.1016\/j.cca.2026.120843_bb0365","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000226048","article-title":"Determination of tissue polypeptide antigen (TPA) levels in different Cancer types and controls","volume":"42","author":"Mross","year":"2009","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0370","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/172460089400900202","article-title":"The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19","volume":"9","author":"Bodenm\u00fcller","year":"1994","journal-title":"Int. J. Biol. Markers"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0375","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/172460080101600201","article-title":"Serum tumor markers: past, state of the art, and future","volume":"16","author":"Thomas","year":"2001","journal-title":"Int. J. Biol. Markers"},{"issue":"Pt 5","key":"10.1016\/j.cca.2026.120843_bb0380","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1258\/acb.2011.011079","article-title":"Metrological traceability in clinical biochemistry","volume":"48","author":"White","year":"2011","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.cca.2026.120843_bb0385","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cca.2017.05.035","article-title":"Stability of lyophilized pooled sera as quality control materials for tumor marker assays in external quality assessment","volume":"471","author":"Ahn","year":"2017","journal-title":"Clin. Chim. Acta"},{"issue":"15","key":"10.1016\/j.cca.2026.120843_bb0390","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.3390\/cancers14153686","article-title":"The significance of external quality assessment schemes for molecular testing in clinical laboratories","volume":"14","author":"Laudus","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.cca.2026.120843_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11112960","article-title":"Clinical applicability of tissue polypeptide antigen and CA-125 in Gynecological malignancies","volume":"11","author":"Schr\u00f6der","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2026.120843_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119110","article-title":"External quality assessment-based tumor marker harmonization simulation; insights in achievable harmonization for CA 15\u20133 and CEA","volume":"558","author":"Van Rossum","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.120843_bb0405","doi-asserted-by":"crossref","first-page":"1401619","DOI":"10.3389\/fmolb.2024.1401619","article-title":"Longitudinal evaluation of external quality assessment results for CA 15-3, CA 19-9, and CA 125","volume":"11","author":"Kremser","year":"2024","journal-title":"Front. Mol. Biosci."},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0410","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1515\/CCLM.2001.089","article-title":"Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer","volume":"39","author":"Tuxen","year":"2001","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0415","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/00365510410006612","article-title":"Minimally processed fresh frozen human reference sera: preparation, testing, and application to international external quality assurance","volume":"64","author":"Henriksen","year":"2004","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.cca.2026.120843_bb0420","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cca.2013.12.032","article-title":"The role of external quality assessment schemes in monitoring and improving the standardization process","volume":"432","author":"Ceriotti","year":"2014","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.cca.2026.120843_bb0425","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1515\/cclm-2017-1179","article-title":"External quality assessment programs in the context of ISO 15189 accreditation","volume":"56","author":"Sciacovelli","year":"2018","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0430","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/gyno.1999.5414","article-title":"Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer","volume":"74","author":"Tuxen","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0435","first-page":"86","article-title":"Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia","volume":"24","author":"Tramonti","year":"2000","journal-title":"Cancer Detect. Prev."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0440","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1515\/cclm-2021-0283","article-title":"Variation, within- and between-subject biological variation data for tumor markers based on the European biological variation study","volume":"60","author":"Co\u015fkun","year":"2022","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"issue":"10","key":"10.1016\/j.cca.2026.120843_bb0445","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/clinchem\/39.10.2077","article-title":"Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation","volume":"39","author":"S\u00f6l\u00e9tormos","year":"1993","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0450","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1515\/cclm-2021-0725","article-title":"Critical review and meta-analysis of biological variation estimates for tumor markers","volume":"60","author":"Marques-Garcia","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0455","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/1097-0142(19940115)73:2<394::AID-CNCR2820730226>3.0.CO;2-Y","article-title":"Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study","volume":"73","author":"Maulard","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2026.120843_bb0460","first-page":"213","article-title":"Tissue polypeptide antigen in the follow-up of patients with urinary bladder cancer compared with conventional urine cytology","volume":"13","author":"Bantis","year":"2010","journal-title":"Hell. J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0465","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00257178","article-title":"Significance of plasma tissue polypeptide antigen determination for diagnosis and follow-up of urothelial bladder cancer","volume":"12","author":"Adolphs","year":"1984","journal-title":"Urol. Res."},{"key":"10.1016\/j.cca.2026.120843_bb0470","first-page":"760","article-title":"Low molecular weight metabolites produced by various penicillium species","volume":"24","author":"Pisarnitski\u012d","year":"1988","journal-title":"Prikl. Biokhim. Mikrobiol."},{"key":"10.1016\/j.cca.2026.120843_bb0475","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1590\/S0034-89101988000500005","article-title":"The 1st indigenous case of south American trypanosomiasis in the state of acre (Brazil) and its correlation with the strains isolated from human cases and from wild triatomines in the area","volume":"22","author":"Barata","year":"1988","journal-title":"Rev. Saude Publica"},{"key":"10.1016\/j.cca.2026.120843_bb0480","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1590\/S0034-89101988000500011","article-title":"The epidemiology and control of schistosomiasis mansoni where Biomphalaria tenagophila is the snail host","volume":"22","author":"Dias","year":"1988","journal-title":"Rev. Saude Publica"},{"key":"10.1016\/j.cca.2026.120843_bb0485","series-title":"The Urinary Proteome: Methods and Protocols","first-page":"303","article-title":"Proteomic assays for the detection of urothelial Cancer","author":"Gaston","year":"2010"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.120843_bb0490","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000474879","article-title":"Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy","volume":"21","author":"Schmidt","year":"1992","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.cca.2026.120843_bb0495","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/BF01211809","article-title":"Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract","volume":"118","author":"van der Gaast","year":"1992","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0500","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/003655901750425828","article-title":"Urine tissue-polypeptide-specific antigen (TPS) as a marker for bladder cancer","volume":"35","author":"Boman","year":"2001","journal-title":"Scand. J. Urol. Nephrol."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0505","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/172460080101600208","article-title":"Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS","volume":"16","author":"Mady","year":"2001","journal-title":"Int. J. Biol. Markers"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0510","first-page":"109","article-title":"Estimation of usefulness of monitoring tissue polypeptide antigen--TPA-M concentrations in the effectiveness surgical treatment of urinary bladder cancer, Nuclear medicine review","volume":"5","author":"Kocha\u0144ska-Dziurowicz","year":"2002","journal-title":"Central & Eastern Europe"},{"issue":"1b","key":"10.1016\/j.cca.2026.120843_bb0515","first-page":"635","article-title":"Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2\/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation","volume":"25","author":"Ecke","year":"2005","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.cca.2026.120843_bb0520","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/cancers13071650","article-title":"Noninvasive urine-based tests to diagnose or detect recurrence of bladder Cancer","volume":"13","author":"Charpentier","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.120843_bb0525","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cca.2012.08.018","article-title":"Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer","volume":"414","author":"Jeong","year":"2012","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369357","article-title":"Molecular markers for bladder Cancer screening, early diagnosis, and surveillance: the WHO\/ICUD consensus","volume":"94","author":"Schmitz-Dr\u00e4ger","year":"2014","journal-title":"Urol. Int."},{"issue":"9","key":"10.1016\/j.cca.2026.120843_bb0535","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.3390\/ijms21093360","article-title":"Diagnostic and prognostic potential of biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in bladder cancers","volume":"21","author":"Matuszczak","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.cca.2026.120843_bb0540","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.21037\/tcr-21-386","article-title":"Diagnostic and prognostic role of BTA, NMP22, survivin and cytology in urothelial carcinoma","volume":"10","author":"Gong","year":"2021","journal-title":"Transl. Cancer Res."},{"issue":"6b","key":"10.1016\/j.cca.2026.120843_bb0545","first-page":"2819","article-title":"Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma","volume":"15","author":"Yao","year":"1995","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0550","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","article-title":"Urine markers for bladder Cancer surveillance: a systematic review","volume":"47","author":"van Rhijn","year":"2005","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.cca.2026.120843_bb0555","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3343\/lmo.2012.2.3.131","article-title":"Evaluation of the performance of Lumipulse G1200 for tumor marker assays","volume":"2","author":"Jin-Hee","year":"2012","journal-title":"Lab Med Online"},{"key":"10.1016\/j.cca.2026.120843_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119902","article-title":"Performance evaluation and characterization of pre-analytical effects by sample types and storage conditions on tumor marker measurement by the point-of-care test platform IchromaTM II","volume":"563","author":"Lee","year":"2024","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0565","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/172460080101600208","article-title":"Cytokeratins as serum markers in Egyptian bladder Cancer. A comparison of CYFRA 21\u20131, TPA and TPS","volume":"16","author":"Mady","year":"2001","journal-title":"Int. J. Biol. Markers"},{"issue":"10","key":"10.1016\/j.cca.2026.120843_bb0570","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cncr.26544","article-title":"The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria","volume":"118","author":"Abogunrin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2026.120843_bb0575","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fonc.2013.00271","article-title":"In situ protein detection for companion diagnostics","volume":"3","author":"Gremel","year":"2013","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0580","first-page":"974","article-title":"Economic evaluation of NMP22 in the management of bladder cancer","volume":"7","author":"Lachaine","year":"2000","journal-title":"Can. J. Urol."},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0585","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urology.2007.08.014","article-title":"Economic impact of tumor markers in bladder Cancer surveillance","volume":"71","author":"Hong","year":"2008","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.cca.2026.120843_bb0590","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.21037\/tcr-20-1990","article-title":"Review of non-invasive urinary biomarkers in bladder cancer","volume":"9","author":"Lee","year":"2020","journal-title":"Transl. Cancer Res."},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0595","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","article-title":"Urine markers for bladder cancer surveillance: a systematic review","volume":"47","author":"van Rhijn","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cca.2026.120843_bb0600","article-title":"In situ protein detection for companion diagnostics","volume":"3\u20132013","author":"Gremel","year":"2013","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.120843_bb0605","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urology.2007.08.014","article-title":"Economic impact of tumor markers in bladder cancer surveillance","volume":"71","author":"Hong","year":"2008","journal-title":"Urology"},{"issue":"18","key":"10.1016\/j.cca.2026.120843_bb0610","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1016\/j.cca.2026.120843_bb0615","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bju.14502","article-title":"Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer","volume":"123","author":"Heijnsdijk","year":"2019","journal-title":"BJU Int."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.120843_bb0620","first-page":"10","article-title":"Tissue polypeptide antigen for monitoring of advanced bladder Cancer after MVEC chemotherapy","volume":"21","author":"Schmidt","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cca.2026.120843_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2025.118209","article-title":"Revealing the role of bisphenol a on prostate cancer progression and identifying potential targets: a comprehensive analysis from population cohort to molecular mechanism","volume":"296","author":"Zhou","year":"2025","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"Pt 3","key":"10.1016\/j.cca.2026.120843_bb0630","article-title":"Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer","volume":"338","author":"Zhou","year":"2025","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0635","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40273-023-01256-9","article-title":"Critical appraisal of decision models used for the economic evaluation of bladder Cancer screening and diagnosis: a systematic review","volume":"41","author":"Mandrik","year":"2023","journal-title":"PharmacoEconomics"},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0640","doi-asserted-by":"crossref","DOI":"10.1097\/JU9.0000000000000271","article-title":"Economic impact model of incorporating Cxbladder monitor in the surveillance of nonmuscle invasive bladder Cancer","volume":"3","author":"Tyson","year":"2025","journal-title":"JU Open Plus"},{"key":"10.1016\/j.cca.2026.120843_bb0645","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2018.10.023","article-title":"Calcitonin gene-related peptide inhibits the cardiac fibroblasts senescence in cardiac fibrosis via up-regulating klotho expression","volume":"843","author":"Li","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.cca.2026.120843_bb0650","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14489","article-title":"A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response","volume":"30","author":"Duan","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"3","key":"10.1016\/j.cca.2026.120843_bb0655","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/BLC-160054","article-title":"A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder Cancer","volume":"2","author":"D\u2019Costa","year":"2016","journal-title":"Bladder Cancer"},{"issue":"6","key":"10.1016\/j.cca.2026.120843_bb0660","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.21037\/tau-20-1327","article-title":"Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?","volume":"10","author":"Humayun-Zakaria","year":"2021","journal-title":"Transl Androl Urol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:50Z","timestamp":1793640590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":132,"alternative-id":["S0009898126000252"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.120843","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue polypeptide antigen as a non-invasive bladder Cancer biomarker","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.120843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120843"}}